Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Safety Should Always Be a Priority With CAR T for Multiple Myeloma: Surbhi Sidana, MD, MBBS
August 7th 2025Cilta-cel’s mechanism of action allows it to penetrate challenging areas of multiple myeloma, providing deep and durable responses even in high-risk patients, explains Surbhi Sidana, MD, MBBS, Stanford University. Still, safety trade-offs should always be a consideration, she adds.
AI Meets Medicare: Inside CMS’ WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Long-Term Lebrikizumab Provides Sustained Skin Clearance in Atopic Dermatitis
August 5th 2025In this subanalysis of data from the ADjoin trial of lebrikizumab, the interleukin-13 receptor inhibitor that is also a monoclonal antibody showed itself to be effective over the long term in patients with atopic dermatitis on maintenance therapy.
Sex-Based Cardiovascular Risks Linked to Cannabinoid Use: Rakendu Rajendran, MBBS
August 4th 2025In this retrospective study, Rakendu Rajendran, MBBS, and colleagues found higher rates of myocardial infarction and major adverse cardiovascular events in males and increased stroke incidence in females, among cannabinoid users.
Recognizing and Addressing Primary Aldosteronism in Hypertension Management: Vivek Bhalla, MD
August 4th 2025Vivek Bhalla, MD, Stanford, calls for greater awareness and implementation of existing screening guidelines to help identify patients who may benefit from more targeted, disease-specific interventions for hypertension in the setting of primary aldosteronism.
Exploring Pregnancy Outcomes in HFpEF and Cardiac Amyloidosis: Rayan Salih, MD
August 4th 2025Rayan Salih, MD, a third-year internal medicine resident with the Northeast Georgia Health System, who hopes to specialize in cardiology, presented the poster, “Double Trouble: Pregnancy Challenges in Heart Failure With Preserved Ejection Fraction and Cardiac Amyloidosis.”
DETECT AS Trial Shows Notification System Closes Care Gaps: Varsha Tanguturi, MD
August 3rd 2025Varsha Tanguturi, MD, cardiologist and DETECT AS investigator, presented new data on how the findings she and her colleagues saw indicate almost universal increases in rates of aortic valve replacement in patients with severe aortic stenosis (AS), across both provider and patient groups.
TikTok's Role in Shaping Cholesterol Knowledge: Khush Kharidia, MD
August 3rd 2025Khush Kharidia, MD, a third-year internal medicine resident at UT Southwestern, presented the oral abstract, “Evaluating the Quality, Accuracy and Health Impact of Cholesterol-Related Content on TikTok: A Social Media Analysis,” at ASPC 2025 Congress on CVD Prevention.
Disparities in Pregnancy-Related Hypertension Among Hispanic Subgroups: Alexandra M. Trevino, MD
August 1st 2025Alexandra M. Trevino, MD, of Northwestern Medicine presented the oral abstract, "Trends in New-Onset Hypertensive Disorders of Pregnancy Among US Adults by Place of Birth and Hispanic Ethnic Origin Group," on day 1 of the ASPC Congress on CVD Prevention.
Health System Fragmentation Undermines Timely Lung Cancer Testing: Julia Rotow, MD
July 31st 2025In this first part of an interview with The American Journal of Managed Care®, Julia Rotow, MD, thoracic oncologist at Dana-Farber Cancer Institute, discusses the critical need to test for biomarkers to afford patients the chance to benefit from recent treatment advances.
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Improved Treatments, Prevention Drive Drop in US Ovarian Cancer Mortality: Muhammad Faizan, MBBS
July 30th 2025The decline in ovarian cancer mortality rates after 2003 can be attributed to advances in treatment, precision medicine, improved preventive strategies, and a reduced disease incidence, according to Muhammad Faizan, MBBS.
Addressing the Hidden Burden of Polycythemia Vera: Andrew Kuykendall, MD
July 29th 2025Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.
Linvoseltamab May Bring Multiple Myeloma Care Closer to Home: Sundar Jagannath, MBBS
July 29th 2025The newly FDA-approved linvoseltamab (Lynozyfic; Regeneron) may improve access to multiple myeloma treatment by offering an off-the-shelf, outpatient option that can be administered in community settings, according to Sundar Jagannath, MBBS.